In addition, plasma biomarkers such as the ratio of amyloid beta (Aβ42/Aβ40), neurofilament light (NEFL/NfL), and glial fibrillary acidic protein (GFAP) hold significant potential for AD diagnosis and monitoring [9, 10]. This evidence concerns the gene GFAP and Alzheimer disease.